McKesson Pays $150M for Opioid Order Cover-Up

TAMPA, FL — McKesson Corporation, one of the nation’s largest pharmaceutical distributors, has agreed to pay a record $150 million civil penalty for systematically failing to report suspicious orders of opioid painkillers, federal prosecutors announced today. The settlement, the largest of its kind in U.S. history, stems from violations of the Controlled Substances Act (CSA) and marks a rare federal crackdown on a drug distribution giant accused of feeding the opioid epidemic.

U.S. Attorney A. Lee Bentley, III, called the penalty a ‘landmark’ action in the Middle District of Florida, where pill mills once ran rampant. ‘Together with the $22 million civil settlement with CVS in 2015, and the $44 million civil settlement with Cardinal Health last year, this settlement demonstrates our willingness to use all remedies at our disposal to encourage corporations and individuals involved in the prescription opioid trade to act responsibly and to punish them when they fail to do so,’ Bentley said.

Special Agent in Charge Adolphus P. Wright of the DEA’s Miami Field Division didn’t mince words: ‘Prescription drug abuse is a public health epidemic and every day, preventable overdoses of prescription pain pills needlessly claim the lives of Floridians.’ He emphasized that national drug distributors are not above the law and condemned McKesson for turning a blind eye to red flags while raking in profits from the crisis.

From 2008 to 2013, McKesson flooded pharmacies across the U.S. with escalating shipments of oxycodone and hydrocodone—two drugs at the heart of the opioid disaster. Despite a 2008 agreement that fined the company $13.25 million for similar failures, McKesson again failed to implement an effective system to detect and report suspicious orders. In Colorado alone, the company processed 1.6 million controlled substance orders yet flagged only 16 as suspicious—most tied to a single terminated customer.

Investigators uncovered that McKesson’s Lakeland, Florida distribution center ignored glaring red flags, including orders for hydromorphone that far exceeded normal pharmacy sales patterns. The DEA found the company’s internal compliance program was either ignored or poorly enforced, allowing dangerous volumes of pills to flow unchecked into vulnerable communities.

The settlement forces McKesson to suspend controlled substance distribution from centers in Colorado, Ohio, Michigan, and Florida for years—among the harshest sanctions ever imposed on a DEA-registered distributor. For the next five years, the company must meet strict compliance mandates, including hiring an independent monitor, increasing staffing, and submitting to audits. Failure to comply triggers additional financial penalties, signaling a new era of federal oversight in the pharmaceutical supply chain.